<DOC>
	<DOCNO>NCT00117299</DOCNO>
	<brief_summary>This study evaluate safety efficacy novel tyrosine kinase inhibitor , PTK787/ZK222584 , treatment GIST ( gastrointestinal stromal tumor ) resistant imatinib mesylate ( Gleevec ) . The study participant require histologically confirm GIST prior imatinib treatment metastatic GIST . administer orally 1250 mg/day . Six patient first enter study . If clinical benefit obtain &gt; 1 6 patient , 9 30 additional patient enter protocol two stage ( maximum 45 patient enter ) . Patients benefit study treatment treat PTK787/ZK222584 treatment failure .</brief_summary>
	<brief_title>PTK787/ZK222584 Treatment Metastatic Gastrointestinal Stromal Tumors Resistant Imatinib</brief_title>
	<detailed_description>This open-label , phase II study PTK787/ZK222584 design determine safety efficacy PTK787/ZK222584 treatment imatinib-resistant GIST . The PTK787/ZK222584 dose use 1250 mg daily . Six patient first enter study use two-stage approach . If clinical benefit obtain &gt; 1 6 patient , 9 30 additional patient enter protocol ( maximum total number 45 patient enter ) . Clinical benefit define occurrence one follow 3 measure : 1 ) objective response PTK787 ( confirm unconfirmed partial response [ PR ] complete response [ CR ] ) ; 2 ) metabolic response define &gt; 50 % decrease standardize uptake value ( SUV ) FDG uptake &gt; 1 FDG-avid lesion one patient ; 3 ) stabilize disease 3 month longer accompany symptomatic performance status improvement . Medical history , current medical condition , weight , height , electrocardiogram record prior study entry . Other baseline examination include chest X-ray , hematologic test , coagulation panel , serum chemistry , urine analysis , serum pregnancy test radiological assessment tumor . Tumor response monitor image 4- 8-week interval . Hematological test serum chemistry evaluate 1- 4-week interval , adverse event collect continuously . Research blood test collect time tumor evaluation . Dose adjustment carry per protocol . Patients benefit study treatment treat PTK787/ZK222584 treatment failure .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<mesh_term>Endothelial Growth Factors</mesh_term>
	<mesh_term>Vatalanib</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Patients histologically confirm GIST Imatinib resistance ( primary resistance progression , progression initial response ) . Resistance define objective evidence progression least 4 week treatment imatinib . Imatinib therapy interrupt &gt; 7 day study entry Metastatic disease confirm histologically , cytologically radiologically Presence measurable tumor lesion determine RECIST criterion Age 18 year old WHO performance status 2 less Blood neutrophil count ( ANC ) 1.5 x 10^9/L high Platelet count 100 x 10^9/L high Serum bilirubin 1.5 x ULN ( upper limit normal ) less Serum creatinine 2.0 x ULN less Written inform consent obtain accord local guideline Patients receive chemotherapy less 4 week prior entry study recover side effect therapy Patients receive cumulative dose doxorubicin &gt; 450 mg/m2 epirubicin 800 mg/m2 Patients receive immunotherapy within 2 week recover side effect therapy Patients receive radiotherapy within 2 week recover side effect therapy Major surgery within 2 week prior entry study patient recover side effect therapy Patients receive investigational drug within 4 week prior entry study recover side effect therapy Patients pregnant breast feeding , adult reproductive potential employ effective method birth control Concurrent severe and/or uncontrolled medical disease ( i.e. , uncontrolled diabetes , congestive cardiac failure , myocardial infarction within 6 month , poorly control hypertension , history labile hypertension , history poor compliance antihypertensive regimen , chronic renal disease , active uncontrolled infection ) could compromise participation study Acute chronic liver disease ( e.g. , hepatitis , cirrhosis ) Confirmed diagnosis HIV infection Impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption PTK787/ZK222584 ( e.g. , ulcerative disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome , bowel obstruction , inability swallow capsules/tablets ) Patients take Coumadin ( warfarin sodium ) ; heparin acceptable . Patients unwilling , unable , comply protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>Gastrointestinal stromal tumor</keyword>
	<keyword>GIST</keyword>
	<keyword>Sarcoma</keyword>
	<keyword>PTK787</keyword>
	<keyword>ZK 222584</keyword>
	<keyword>Tyrosine kinase inhibitor</keyword>
	<keyword>Tyrosine kinase</keyword>
	<keyword>VEGF</keyword>
	<keyword>Vascular endothelial growth factor</keyword>
	<keyword>VEGFR</keyword>
	<keyword>Vascular endothelial growth factor receptor</keyword>
	<keyword>KDR</keyword>
	<keyword>KIT</keyword>
	<keyword>c-KIT</keyword>
	<keyword>Platelet derive growth factor receptor</keyword>
	<keyword>PDGFR</keyword>
</DOC>